Current treatment for ovarian cancer

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 1, 2001, Pages 109-124

  Eltabbakh, G H ^a   Awtrey, C S ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Adjuvant chemotherapy; Carboplatin; Cisplatin; Cytoreductive surgery; Ovarian cancer; Paclitaxel; Treatment

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; PACLITAXEL; TAMOXIFEN; TOPOTECAN;

ABDOMINAL HYSTERECTOMY; ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG SENSITIVITY; EARLY CANCER; FATIGUE; FEMALE; HEARING LOSS; HUMAN; LYMPHADENECTOMY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PROGNOSIS; REVIEW; SALPINGOOOPHORECTOMY; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SALVAGE THERAPY;

EID: 0035002586     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.1.109     Document Type: Review

References (76)

1. Cancer statistics, 2000
2. The cancer and steroid hormone study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use
3. Ovarian tumours in a cohort of infertile women
4. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: Results of a case-control study
5. Analysis of prognostic factors in stage I epithelial ovarian cancer. Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse
6. Surgical resection of tumour bulk in the primary treatment of ovarian cancer
7. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma
8. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
9. Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy
10. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study
11. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: Results from two prospective randomized trials
12. Intraperitoneal radioactive phosphorous therapy in ovarian cancer: Analysis of 313 patients treated primarily or by second-look laparotomy
13. Adjuvant treatment for early epithelial ovarian cancer: Results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)
14. Controversial issues in the management of early epithelial ovarian cancer: Conservative surgery and role of adjuvant therapy
15. Review of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumour Institute
16. A randomized comparison of melphalan versus melphalan plus hexamethylamine versus adriamycin plus cyclophosphamide in ovarian carcinoma
17. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma
18. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer
19. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiamine-platinum (II), adriamycin and cycholphosphamide: A preliminary report
20. Phase II study of cis-dichlorodiamine-platinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary
21. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs. CP) in advanced ovarian carcinoma
22. Randomized comparison of cisplatin with cyclophosphamide and cisplatin and cyclophosphamide with doxorubicin in advanced ovarian cancer
23. A randomized study of cyclophosphamide and cisplatin with or without doxorubicin in advanced ovarian cancer
24. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide in advanced ovarian cancer
25. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis
26. Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials
27. Amifostine pretreatment for protection against cyclophosphamide-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer
28. Dose optimization of carboplatin in adults
29. Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients
30. High dose cisplatin and high dose carboplatin in refractory cancer
31. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma
32. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study
33. A randomized study of high versus standard dose carboplatin in patients with advanced epithelial ovarian cancer
34. Cisplatin (P) dose intensity in advanced ovarian cancer (AOC): A randomized study of conventional dose (DC) versus dose-intensity (DI) cisplatin monochemotherapy
35. Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cytoxan - The Indiana University experience
36. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ouest
37. Prospective randomized trial of cisplatin/carboplatin versus conventional cisplatin/cyclophosphamide in epithelial ovarian cancer: First results of the impact of platinum dose intensity on patients' outcome
38. A randomized study of high-dose versus low-dose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian cancer
39. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer
40. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results
41. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide and autologous bone marrow rescue: High response rate for refractory ovarian carcinoma
42. High-dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: A retrospective analysis of 35 patients treated in France
43. High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer
44. Intraperitoneal cisplatin with systemic thiosulphate protection
45. Intraperitoneal chemotherapy
46. Intraperitoneal cisplatin plus iv. cyclophosphamide versus iv. cisplatin plus iv. cyclophosphamide for stage III ovarian cancer
47. Phase I trial of ip. Taxol: A Gynecologic Oncology Group study
48. The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: 'Maintenance' therapy reconsidered
49. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin and cisplatin (CAP) in stage III and IV ovarian cancer
50. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group trial (DACOVA)
51. The taxoids: Paclitaxel and docetaxel
52. Paclitaxel (Taxol)
53. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103
54. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
55. Is cisplatin-paclitaxel the standard in first-line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCI-C and Scottish Intergroup experience
56. Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial
57. Paclitaxel delivered as a 3-hour infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity
58. Taxol in relapsed ovarian cancer: High versus low dose and short versus long infusion: A European-Canadian study co-ordinated by the NCI Canada Clinical Trialists Group
59. Sequences of Taxol and cisplatin: A Phase I and pharmacologic study
60. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study
61. Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival
62. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer
63. Carboplatin and paclitaxel in ovarian carcinoma: A Phase I study of the Gynecologic Oncology Group
64. Randomized Phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO/PAC) in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158)
65. Cisplatin/paclitaxel versus carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynäekologische Onkologie (AGO) study group trial
66. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced epithelial ovarian carcinoma
67. A Phase II trial of ip. cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment
68. Influence of secondary cytoreduction at the time of second look laparotomy on the survival of patients with epithelial ovarian carcinoma
69. Secondary cytoreduction for ovarian cancer following cisplatin therapy
70. Secondary cytoreductive surgery
71. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer
72. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
73. Topotecan in platinum and paclitaxel-resistant ovarian cancer
74. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel
75. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumour activity and toxicity modification by liposomal encapsulation
76. Prolonged oral etoposide as second line therapy for platinum-resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group study